Source:http://linkedlifedata.com/resource/pubmed/id/20064707
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2010-3-8
|
pubmed:abstractText |
Increased levels of circulating VEGF-A have been demonstrated in patients with non-Hodgkin lymphoma (NHL) and are associated with progressive disease and poor clinical outcome. We investigated the role of VEGF-A in lymphoma tumour growth on a molecular level in order to identify the mechanism of VEGF-A-promoted tumour growth and to identify the potential targets for therapy. We used a model in which Daudi (human Burkitt lymphoma) tumour cells were transduced with VEGF-A165 or an empty vector (negative control) and subcutaneously injected in NOD/SCID mice. The weight of tumours overexpressing VEGF-A was increased 4-fold compared to that of control tumours (p<0.0001), whereas no in vitro growth advantage was demonstrated upon VEGF-A overexpression. VEGF-A-tumours were associated with increased microvessel densities (p=0.004) and increased tumour cell proliferation (Ki67; p<0.001) compared to control tumours. VEGF-A-tumours were characterised by upregulation of phosphorylated STAT-4 and STAT-6 and downregulation of phospho-p27(KIP1), a crucial cell cycle inhibitor (p<0.05). This was accompanied by increased levels of phosphorylated receptor tyrosine kinases, including EGFR (ErbB-2 and ErbB-4, p<0.05), an upstream regulator of STAT proteins. We demonstrated that various mouse-derived cytokines produced by mouse-derived tumour stromal cells are upregulated in VEGF-A-tumours compared to control tumours (p<0.05). These results indicate an important role for the tumour microenvironment in paracrine promotion of lymphoma tumour growth in response to tumour-derived VEGF-A. In conclusion, lymphoma-derived VEGF-A promoted lymphoma tumour growth in a paracrine loop by activation of tumour stromal cells. Our study reveals VEGF-A and STAT proteins as potential additional targets in the treatment of lymphoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor Protein-Tyrosine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/STAT Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1879-0852
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2009 Elsevier Ltd. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
46
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
974-82
|
pubmed:meshHeading |
pubmed-meshheading:20064707-Animals,
pubmed-meshheading:20064707-Burkitt Lymphoma,
pubmed-meshheading:20064707-Cyclin-Dependent Kinase Inhibitor p27,
pubmed-meshheading:20064707-Cytokines,
pubmed-meshheading:20064707-Disease Models, Animal,
pubmed-meshheading:20064707-Humans,
pubmed-meshheading:20064707-Mice,
pubmed-meshheading:20064707-Mice, Inbred NOD,
pubmed-meshheading:20064707-Mice, SCID,
pubmed-meshheading:20064707-Neoplasm Proteins,
pubmed-meshheading:20064707-Paracrine Communication,
pubmed-meshheading:20064707-Receptor Protein-Tyrosine Kinases,
pubmed-meshheading:20064707-STAT Transcription Factors,
pubmed-meshheading:20064707-Stromal Cells,
pubmed-meshheading:20064707-Vascular Endothelial Growth Factor A
|
pubmed:year |
2010
|
pubmed:articleTitle |
VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms.
|
pubmed:affiliation |
Division of Pediatric Oncology/Hematology, Department of Pediatrics, University Medical Center Groningen, University of Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
|
pubmed:publicationType |
Journal Article
|